%0 Journal Article
%T Predictive value of D-Dimer and thromboplastin time as coagulation indicators for COVID-19 patients.
%A Alshipli M
%A Altaim TA
%A Oglat AA
%A Ahmed Alsenany S
%A Khodrog O
%A Hasan H
%A Mohammed Farghaly Abdelaliem S
%A Matrieh A
%A Shakhreet BZ
%A Gaowgzeh RA
%J J Infect Dev Ctries
%V 18
%N 5
%D 2024 May 30
%M 38865388
%F 2.552
%R 10.3855/jidc.18593
%X <B>BACKGROUND: </B>Coronavirus 2019 symptoms include coagulopathy and thromboembolic risk. Using one parameter to diagnose coagulopathy has little predictive value.<BR><B>OBJECTIVE: </B>This study will examine if D-dimer and APTT testing can predict COVID-19 severity and aid triage and manage patients.<BR><B>METHODS: </B>214 COVID-19 patients were enrolled and classified into two categories based on their respiratory manifestations; mild (126 cases) and severe (88 cases). Patient data regarding age, gender, D-Dimer level, and APTT level were collected. When both D-Dimer and APTT levels were abnormal, in this study, the patient was considered to have a coagulation disorder. Indicators of coagulation in the COVID-19 patients were collected and compared between the two groups. Chi-square (χ2) tests were used to determine the significant differences between coagulation disorders in the two groups.<BR><B>RESULTS: </B>Our findings showed that patients with coagulopathies were more likely to belong to the severe group. Within the two groups of patients, the rate of coagulation disorders was as follows: mild = 8.8 % within coagulation disorders, 4.8% within the two Groups; severe = 91.2 % within coagulation disorders, 77.8 % within the two Groups. There was a statistically significant relationship between coagulation disorder and severe COVID-19 patients compared to mild patients (p < 0.05).<BR><B>CONCLUSIONS: </B>Coagulation disorders are more likely to occur in severe COVID-19 patients. D-Dimer and APTT tests are significant indicators for predicting COVID-19 severity. Our research found an abnormal pattern of coagulation disorders and COVID-19 severity that should be considered in the COVID-19 treatment protocol.